Answers are grounded in this paper and cite their sources.
Shows estimated survival reaching 93.3% in transfusion-dependent thalassemia, indicating therapeutic advances alongside stark global inequities in treatment access.
In this issue of the American Journal of Hematology, Forni et al. update their long-term assessment of the anticipated lifespan and associated morbidity in a well-defined population of patients with thalassemia.1 Periodic re-evaluation of survival of patients with a particular life-threatening disease can sometimes fill the reader with despair rather than hope or even a record of progress. This might well have been the response to the first 40–50 years after Doctors Cooley and Rietti separately identified what we now call thalassemia in 1925. There was little reason for hope and only small steps of progress despite wider recognition and characterization of the clinical disorder as well as early engagement of patient advocacy groups. On the other hand, amidst the despair there may be inspiration born of demonstrated need and nurtured by scientific advances. Beginning in the late 1960s, that inspiration contributed to important improvements in access to donor blood, particularly safe blood, and the related recognition that maintaining higher hemoglobin levels in patients with transfusion-dependent thalassemia would contribute to longer lives of greater quality. (As a footnote, one of the strongest advocates of more intensive transfusion was Dr. Irving Wollman with whom I briefly worked while in medical school. However, the unsung hero in his work was his personal assistant Margaret Wickersham, a force to be reckoned with in her own right. She tracked each hemoglobin level and made sure that patients were transfused on schedule. It is possible she even wrote some of the orders.) With the advent of more intensive transfusion therapy, the need for effective iron chelators became an imperative, and the first such drug, deferoxamine, was developed and its parenteral administration refined beginning in the 1970s.2 Amidst this progress there was an increasing recognition that improved life expectancy for patients with thalassemia would require further improvement in transfusion medicine, chelator development, and monitoring of complications such as iron-induced organ damage. Prevention of transfusion-transmitted infections such as hepatitis B, HIV, and hepatitis C was followed by noninvasive measurement of iron in the heart and liver.3, 4 In the midst of these advances and despite a variety of entanglements that showed both the fragility and importance of scientifically sound relationships between investigators and the pharmaceutical industry, two orally active iron chelators, deferiprone, and deferasirox, became critical tools in addressing the major cause of early death in patients with thalassemia.5, 6 Both prevention and cure entered the thalassemia vocabulary in the form of large prenatal testing programs and the first successful allogeneic bone marrow transplant.7, 8 Since 1983, a collaboration among seven large Italian thalassemia centers has followed the improvement in long-term survival and has explored epidemiologic, clinical, and laboratory correlates of change. Subjects in the initial cohort were born between 1970 and 1974, and results were published in 1989. Subsequent publications added later birth cohorts with the last update published nearly 20 years ago. Given the recent changes in care, the current assessment of a new birth cohort by Forni et al could not come at a better time and the results are very impressive. The current birth cohort (1985–1997) has an estimated survival of 93.3%. Equally striking is the consistent improvement in survival since the first analysis, and the dramatic reduction in deaths due to cardiac complications, the leading cause of mortality in thalassemia for many decades. There are other jewels in this report. The use of splenectomy has declined as good transfusion practices have reduced the incidence of hypersplenism and as the complications of asplenia, particularly thrombosis, have received more attention. The age at the time of bone marrow transplantation has fallen precipitously, 3.8 years in the latest cohort. Notably, no deaths related to bone marrow transplantation have occurred since 2010, a remarkable achievement. The importance of this updated analysis of the large cohort is magnified by the recent FDA approval of the first gene therapy for transfusion-dependent thalassemia, and the accumulating information from other gene addition and gene editing trials.9-11 The data from the paper by Forni et al. will be a critical reference point for discussions with patients and families considering curative therapies, now including both bone marrow transplantation and gene therapy. At last there will be choices, something that has been lacking for much of the history of this disease and is now expanding at a rapid rate. The findings from the longitudinal study of the Italian cohort now have a new and crucial role in the clinic. The paper by Forni et al. carries another equally important message. The same advances that underlie the exciting changes in survival and other outcomes in the Italian cohort also cast in stark relief the widening gap in thalassemia care for those in under-resourced and well-resourced medical environments.12 A safe donor blood supply may be tenuous, invaluable diagnostic tools such as MRIs for iron measurements may be unavailable, and even daily chelation therapy may be out of reach. Needless to say, the cost and necessary technology of curative therapies present an unimaginable barrier in many parts of the world. Many others have pointed to the irony in the lack of resources in countries where thalassemia is most prevalent. While the work by Forni et al. certainly helps to identify the important contributors to improved survival, parallel efforts will be required to discover ways to make these contributors affordable. Otherwise, we will continue to discuss the prevalence of thalassemia as a worldwide disorder while discussing the improved survival of affected patients in a much smaller portion of that world. The authors declare no conflicts of interest. Data sharing is not applicable to this article as no new data were created or analyzed in this study.
No takes yet. Share an insight, caveat, or question.
Alan R. Cohen (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: